Why the study?
Does bedside genotyping identify defective CYP2C19*2 alleles in CAD patients with stent thrombosis or high on-treatment platelet reactivity?
Does bedside genotyping identify defective CYP2C19*2 alleles in CAD patients with stent thrombosis or high on-treatment platelet reactivity?
Bedside genotyping can rapidly identify CYP2C19*2 alleles in CAD patients with stent thrombosis or high platelet reactivity, potentially guiding personalized antiplatelet therapy.
Bedside CYP2C19 genotyping is feasible in <1 hour among CAD patients; hypothesis-generating for personalized antiplatelet therapy and requires prospective validation.
Objective. The task was to identify the defective CYP2C19*2 allele by using a novel fast-genotyping method in the patients having coronary artery disease who developed stent thrombosis or high on-treatment platelet reactivity. Materials and methods. A total of 35 patients were included in the study. All the patients were screened for CYP2C19*2 using Spartan RX CYP2C19 Assay Package. Results. CYP2C19*1*1 variant was found in 63%, *1*2 in 34%, *2*2 in 3% of patients. The distribution of genotypes was similar in men and women. Conclusions. By using the bedside technique, CYP2C19*2, which is responsible for a poorer effect of clopidogrel, might be identified in less than an hour.
No takes yet. Share an insight, caveat, or question.
Karaliūtė et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: